Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04178005 · ClinicalTrials.gov registry record · Phase 4

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

A Phase 4 study of Multiple Sclerosis, sponsored by University of Texas Southwestern Medical Center.

Active
Registry status
Phase 4
Development phase
40
Enrollment target
2
Study locations

NCT04178005: Active Phase 4 study of Multiple Sclerosis, sponsored by University of Texas Southwestern Medical Center.

NCT04178005 is a Phase 4 study of Multiple Sclerosis that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 40 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04178005, a Phase 4 study of Multiple Sclerosis, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS).

Primary Outcome

The absolute and percent change from baseline will be presented for each time point for CD3+ T lymphocytes, CD19+ B lymphocytes, CD11c+ DC subsets, NfL levels in blood, with a two-sided 95% CI and p value. As these data are not expected to be normally distributed, the nonparametric Wilcoxon signed rank test will be used to compare each biomarker at baseline and during treatment. Spearman rank correlations will be used to examine the relationship between biomarkers and clinical/safety endpoints.

Conditions Studied

Interventions

  • DRUG Cladribine

Study Locations (2)

Kansas

  • College Park Family Care Center Physicians Group - Overland Park

Texas

  • UT Southwestern Medical center - Dallas

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-02-19
Est. Completion 2026-12
Phase Phase 4

What the registry record for NCT04178005 still lists

NCT04178005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Cladribine is the first listed.

NCT04178005 reports a single indexed study location in Kansas, Texas.

Frequently Asked Questions

What is clinical trial NCT04178005 about?

NCT04178005 is a clinical study titled "Cladribine Tablets After Treatment With Natalizumab (CLADRINA)". The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS).

What is the current status of trial NCT04178005?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2020-02-19. Estimated completion is 2026-12.

What conditions does trial NCT04178005 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT04178005?

The interventions under investigation include: Cladribine (DRUG).

Who is sponsoring clinical trial NCT04178005?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04178005 being conducted?

This trial has 2 study locations across Kansas, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04178005's enrollment target sits among peer trials

40 197th of 315 higher than 108 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04178005, the US trial registry maintained by the National Library of Medicine. NCT04178005 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.